Vanguard Capital Management
HUMA icon

Vanguard Capital Management’s Humacyte HUMA Stock Holding History

Vanguard Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88M Buy
10,107,679
+2,949,517
+41% +$2.73M ﹤0.01% 2948
2026
Q1 		$4.35M Buy
+7,158,162
New +$7.44M ﹤0.01% 3114

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management's HUMA Position: Q2 2026 in Review

Vanguard Capital Management increased its Humacyte (HUMA) stake by 41% in Q2 2026, buying an estimated $2.73M and bringing the position to 10,107,679 shares worth $7.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2948.

Vanguard Capital Management first reported a position in HUMA in Q1 2026 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Vanguard Capital Management held 10,107,679 shares of Humacyte worth $7.88M as of Q2 2026.
  • Vanguard Capital Management bought 2,949,517 Humacyte shares in Q2 2026, an estimated $2.73M.
  • Humacyte made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2948 holding.
  • Vanguard Capital Management first reported a position in Humacyte in Q1 2026 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.